How do you approach patients with MAC lung disease who are “treatment refractory” to their initial drug regimen?

How do you approach patients with MAC lung disease who are “treatment refractory” to their initial drug regimen?

How do you approach patients with MAC lung disease who are “treatment refractory” to their initial drug regimen? 


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Patrick Flume, MD

Patrick Flume, MD

Professor of Medicine and Pediatrics
Medical University of South Carolina
Powers-Huggins Endowed Chair for Cystic Fibrosis
University of South Carolina
Charleston, South Carolina